Abstract Mutations in WFS1 are reported to be responsible for two conditions with distinct phenotypes; DFNA6/ 14/38 and autosomal recessive Wolfram syndrome. They differ in their associated symptoms and inheritance mode, and although their most common clinical symptom is hearing loss, it is of different types. While DNFA6/14/38 is characterized by low frequency sensorineural hearing loss (LFSNHL), in contrast, Wolfram syndrome is associated with various hearing severities ranging from normal to profound hearing loss that is dissimilar to LFSNHL (Pennings et al. 2002) . To confirm whether within non-syndromic hearing loss patients WFS1 mutations are found restrictively in patients with LFSNHL and to summarize the mutation spectrum of WFS1 found in Japanese, we screened 206 Japanese autosomal dominant and 64 autosomal recessive (sporadic) non-syndromic hearing loss probands with various severities of hearing loss. We found three independent autosomal dominant families associated with two different WFS1 mutations, A716T and E864K, previously detected in families with European ancestry. Identification of the same mutations in independent families with different racial backgrounds suggests that both sites are likely to be mutational hot spots. All three families with WFS1 mutations in this study showed a similar phenotype, LFSNHL, as in previous reports. In this study, onethird (three out of nine) autosomal dominant LFSNHL families had mutations in the WFS1 gene, indicating that in non-syndromic hearing loss WFS1 is restrictively and commonly found within autosomal dominant LFSNHL families.
Introduction
WFS1 is a gene encoding an 890 amino-acid glycoprotein (wolframin), predominantly localized in the endoplasmic reticulum. Mutations in WFS1 are reported to be responsible for both non-syndromic and syndromic forms of hearing loss: autosomal dominant low-frequency sensorineural hearing loss (LFSNHL) DFNA6/14/38, as well as autosomal recessive Wolfram syndrome. Both conditions are distinct with regard to phenotype, not only in associated symptoms and inheritance mode, but also in their mutual clinical symptom of hearing loss, which is manifested by different types. LFSNHL DFNA6/14/38 is a rare, but clearly differentiated type of hearing loss affecting the low frequencies (2,000 Hz and below) that worsens over time, but does not progress to profound deafness. Wolfram syndrome is characterized by diabetes mellitus, diabetes insipidus, optic atrophy (Strom et al. 1998; Inoue et al. 1998 ) and normal or high/all frequency hearing loss with various hearing severities ranging from mild to profound (Pennings et al. 2004) . Since WFS1 mutations have been found in various types of hearing loss, it was an interesting question whether WFS1 mutations could be found in nonsyndromic hearing loss patients with other than LFSNHL, but there had been no reports of mutation screening for various phenotypes of hearing.
Twenty-six heterozygous WFS1 mutations for non-syndromic hearing loss and 110 WFS1 mutations for Wolfram syndrome have been identified. Mutation spectrums of deafness genes, including GJB2 and SLC26A4, have been shown to be dependent on ethnic background (Ohtsuka et al. 2003; Tsukamoto et al. 2003) , and therefore whether there is a unique WFS1 mutation spectrum in Japanese (most probably representative of other Asian populations) was also of interest.
The present study was carried out to (1) confirm the phenotype (whether within non-syndromic hearing loss patients WFS1 mutations are found restrictively in those with LFSNHL) and (2) summarize the mutation spectrum of WFS1 found in Japanese. To do so, we screened 206 Japanese autosomal dominant and 64 autosomal recessive (sporadic) non-syndromic hearing loss probands with various severities of hearing loss.
Materials and methods

Subjects
Two-hundred and six Japanese autosomal dominant (AD; with two or more generations affected) and 64 autosomal recessive (AR; normal hearing parents and more than two affected siblings or recessive compatible sporadic cases) sensorineural hearing loss patients were screened for mutations in the WFS1 gene. All probands were from independent families, and none had any other associated neurological signs, visual dysfunction or diabetes mellitus. Severity of hearing loss was classified by a pure-tone average over 500, 1,000, 2,000 and 4,000 Hz in the better hearing ears as follows: normal hearing, <20 dB; mild hearing loss, 21-40 dB; moderate hearing loss, 41-70 dB; severe hearing loss, 71-95 dB; and profound hearing loss, greater than 95 dB (GENDEAF 2004) . The severity of hearing loss was classified from normal to profound: normal (only limited frequencies involved) in 12/0 patients (<20 dB), mild (21-40 dB) in 43/12 (21/19%), moderate (41-70 dB) in 96/16 (47/25%), severe (71-95 dB) in 32/9 (16/14%) and profound (>95 dB) in 23/27 (11/42%) (dominant/recessive respectively). The age of onset varied from congenital to 60/50 years (dominant/recessive respectively). The type of hearing loss was low frequency (2,000 Hz and below) involved in 9/3 patients (4/5%), high frequency (2,000 Hz and above) involved in 14/12 patients (7/19%), and all frequencies involved in 183/49 patients (89/76%) (dominant/recessive, respectively).
The control group consisted of 86 unrelated Japanese individuals with normal hearing evaluated by auditory testing. All subjects gave prior informed consent for participation in the project, and the Ethical Committee of Shinshu University approved the study.
Mutation analysis
All eight exons and flanking intronic sequences except for exon 1 of the WFS1 gene were amplified by polymerase chain reaction PCR. Primers were designed to flank all of the exon-intron boundaries through use of the Primer3 webbased server (http://www-genome.wi.mi.edu/cgi-bin/primer/primer3_www.cgi). Each genomic DNA sample (40 ng) was amplified using Ex-Taq polymerase (Takara) for 5 min at 95°C, followed by 37 three-step cycles of 95°C for 30 s, 56-63°C for 30 s and 72°C for 1.5 min, with a final extension at 72°C for 10 min, ending with a holding period at 4°C in a Perkin-Elmer thermal cycler. The PCR products varied in size at about 200-700 bp, and they were treated with 0.1 ll exonuclease I (Amersham) and 1 ll shrimp alkaline phosphatase (Amersham) and by incubation at 37°C for 30 min, and inactivation at 80°C for 15 min. After the products were purified, we performed standard cycle sequencing reaction with ABI Big Dye terminators in an ABI 3100 autosequencer (Applied Biosystems).
Results
Direct DNA sequencing identified two disease-causing mutations from AD families ( Fig. 1) , however no mutations were found in AR families. Twenty-eight polymorphisms were found among the studied subjects (Table 1) . Family #1 had a heterozygous G fi A transition at nucleotide 2,146 in exon 8, which results in an alanine-to-threonine substitution at codon 716 (A716T). Families #2 and #3 had a heterozygous G fi A transition at nucleotide 2,590 in exon 8, which results in a glutamic acid-to-lysine substitution at codon 864 (E864K). Genetic analysis showed cosegregation of E864K with LFSNHL in the family members available to be examined. In contrast, none of the 86 normal controls had these mutations. All of the patients with WFS1 mutations showed dominant inherited LFSNHL, and mutations were not found in dominant families with other types of hearing loss or recessive/sporadic families. Onethird (three out of nine) autosomal dominant LFSNHL families had mutations in the WFS1 gene.
Discussion
We found three independent autosomal dominant families associated with two different WFS1 mutations. All patients showed LFSNHL as previously reported in DFNA6/14/38 (Bespalova et al. 2001; Young et al. 2001; Eiberg et al. 2006) . WFS1 mutations were not found in recessive families (even in the patients with lower frequency involved hearing loss), nor in other types of hearing loss, indicating that in non-syndromic form of hearing loss they can be found only in dominant families with LFSNHL. Despite the recent considerable advances in the discovery of deafness genes, clinical application still entails difficulties because of the genetic heterogeneity of deafness. Although nearly 100 genes are estimated to be responsible for hereditary hearing loss (Morton 1991) , in general, many may cause similar phenotypes without any abnormality other than hearing loss. However, this particular type of hearing loss (LFSNHL) can be easily distinguished from others by audiogram. Attention should be paid to this when performing genetic testing, and WSF1 should be the first gene to be screened for this category of patients. In addition, it must be remembered that the newborn hearing screening methods that are commonly used do not detect hearing loss that affects frequencies below 2,000 Hz, requiring children at risk to receive special monitoring. LFSNHL is usually diagnosed by the age of 10 years and thereafter gradually progresses over a long period. Quite often young patients with LFSNHL show no symptoms and therefore do not use hearing aids, but in later life they may develop high-frequency loss, affecting speech perception. Routine monitoring has often not been performed even for children in families with a strong history of dominant LFSNHL. In the subjects of this study, hearing loss was noticed between 5 and 14 years old (mean: 10 years old), and three of nine patients used hearing aids. In DNFA6/14/ 38 there is no or only mild progression of hearing loss. Some patients have also reported tinnitus, but none reported vertigo or dizziness (Young et al. 2001; Lesperance et al. 2003; Pennings et al. 2003) . In the present study, two out of nine patients noticed tinnitus, but none had progression of hearing loss or vertigo, in line with the previously reported phenotype.
In the present study, two mutations, A716T and E864K, previously reported in families with European ancestry, were found in three Japanese families. Until now, 26 WFS1 mutations have been reported to be associated with DFNA6/ 14/38 (Table 2) , and this is the first example of WFS1 mutations found across different racial backgrounds. A similar presumed hot spot in a deafness gene found across different ethnicities by haplotype analysis is the KCNQ4 missense mutation, W276S (van Camp et al. 2002) .
The A716T mutation has been reported to be associated with six independent families of different racial backgrounds, including the present family, suggesting that it is likely to be a hot spot rather than due to a founder effect. Also E864K, found in two independent Japanese families in this study, has recently been reported in a family with European ancestry, indicating that this mutational site is also a possible hot spot. The present two mutations are situated in exon 8, consistent with the tendency for mutations to be accumulated in that exon. Wolfram syndrome mutations are spread over the entire coding region and are typically inactivating, suggesting that a loss of function causes the disease phenotype. In contrast, only non-inactivating mutations have been found in DFNA6/14/38 families, and these mutations are mainly located in the C-terminal protein domain.
Until now the function of the protein wolframin, the WFS1 gene product, has been unknown. In the brain, wolframin is restricted to certain populations of neurons, including the ventral cochlear nucleus and the inferior colliculus. However, analysis of the cochlear expression of wolframin using immunohistochemistry showed no differences in staining pattern or gradients of expression between the basal and apical parts of the cochlea (Cryns et al. 2003a) . Wolframin is a membrane glycoprotein that is primarily localized in the endoplasmic reticulum, where it may serve as a calcium channel or regulator of calcium channel and is thought to be an integral, endoglycosidase H-sensitive membrane glycoprotein (Inoue et al. 1998; Takeda et al. 2001) . Wolframin can be an integral, endoglycosidase H-sensitive membrane glycoprotein that is localized primarily in the endoplasmic reticulum. This localization suggests that this protein plays a yet undefined role in membrane trafficking, protein processing and/or regulation of calcium homeostasis (Takeda et al. 2001) . Additionally, in a recent study, it was suggested that ERstress and N-glycosylation play important roles in wolframin expression and stability (Yamaguchi et al. 2004; Yamada et al. 2006) .
Wolfram syndrome is a rare autosomal recessive neurodegenerative disorder of juvenile onset, also known as DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy and deafness). Minimal diagnostic criteria are diabetes and optic atrophy unexplained by any other disease. Other less frequent features include psychiatric abnormalities, ataxia, urinary tract atony, limited joint motility, cardiovascular and gastrointestinal autonomic neuropathy, hyper-gonadotropic hypogonadism, heart malformations and anterior pituitary dysfunction (Strom et al. 1998; Inoue et al. 1998) . Although none of the present patients had diabetes mellitus or optic atrophy, a recent report described patients with heterozygous E864K associated with optic atrophy (Eiberg et al. 2006 ) and a patient with homozygous A716T and diabetes mellitus (Young et al. 2001) . Discrepancy between phenotypes of the same gene is difficult to explain, but similar phenotypic variation with the same mutation has been known in hearing loss with the SLC26A4 gene (Tsukamoto et al. 2003) , and other environmental and/or genetic factors may contribute to this.
In the present study, various WFS1 sequence variants were found (Table 1) . In the present patients, no apparent phenotype appeared to be associated with these single nucleotide polymorphisms, although several WFS1 sequence variants have previously been shown to be significantly associated with diabetes mellitus and psychiatric diseases (Cryns et al. 2003b) . Additional genotype-phenotype correlation study will clarify the detailed phenotypic range caused by WFS1 mutations. 
